Cystatin C adaptation in the first month of life

Insights

This study details cystatin C levels in newborns, offering insights into kidney function markers. However, methodological concerns question its use as a sole reference for infant kidney health.

Area of Science:

  • Pediatric Nephrology
  • Neonatal Research
  • Biomarker Analysis

Background:

  • Investigates cystatin C concentrations in neonates up to 30 days old.
  • Addresses a knowledge gap in cystatin C levels beyond 72 hours post-birth.
  • Includes both preterm and term neonates in the study cohort.

Discussion:

  • Highlights methodological limitations, including potential inclusion of neonates with impaired glomerular filtration rate (GFR).
  • Questions the validity of the data as pure reference intervals for infants up to one month.
  • Suggests that exposure to nephrotoxic drugs may affect cystatin C concentrations.

Key Insights:

  • Provides detailed cystatin C data by day of life and post-conceptional age.
  • Identifies potential confounding factors affecting GFR marker interpretation in neonates.
  • Emphasizes the need for robust reference intervals for neonatal kidney function assessment.

Outlook:

  • Proposes a global collaboration for establishing age-independent z-scores and percentiles for GFR markers.
  • Recommends using Box-Cox transformations, similar to growth chart methodologies.
  • Suggests improved definitions for acute kidney injury in infants based on GFR marker percentiles.

Related Concept Videos

Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Adaptability of Cytoskeletal Filaments01:12

Adaptability of Cytoskeletal Filaments

The cytoskeleton is a complex dynamic structure performing varied functions based on cellular requirements. The adaptability of the individual filaments in the cytoskeleton determines their ability to perform various functions within the cell. It can undergo rapid reorganization during processes like cell division or remain stable for several hours as in the interphase. The adaptability of these filaments depends on stringent regulatory mechanisms. The microfilament and microtubules of the...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Cellular Adaptation I: Introduction and Atrophy01:23

Cellular Adaptation I: Introduction and Atrophy

Cells can adapt to environmental changes to maintain function and avoid injury, a process called cellular adaptation. Adapted cells exist in a reversible intermediate state with changes in size, number, phenotype, metabolism, or function. These responses help cells meet altered physiological or pathological demands; for example, enlargement of breast and uterine tissues during pregnancy. Early adaptations may enhance function, but persistent stress eventually causes tissue damage.Types of...